John Fischer

John Fischer is a Senior Director at Cogent Biosciences, a position held since April 2021, following a progression through roles including Director and Research Fellow. Prior experience includes nearly two decades at Array BioPharma Inc./Pfizer as a Medicinal Chemist, where John Fischer contributed to the development of various clinical assets, notably MRTX1133 (Kras G12D Inhibitor), MRTX849 (Kras G12C Inhibitor), ARRY-558 (Shp2 Inhibitor), and ARRY-403/AMG151 (Glucokinase Activator). John Fischer possesses extensive expertise across multiple therapeutic indications.